| Molecular formula | C16H22N6O4 |
|---|
| Molecular weight | 362.38 g/mol |
|---|
| Registered trials | 21 |
|---|
| PubChem CID | 638678 |
|---|
What protirelin is
Protirelin is a synthetic peptide with the molecular formula C16H22N6O4 and a molecular weight of about 362.38 g/mol (PubChem CID 638678). It corresponds to thyrotropin-releasing hormone (TRH), a small peptide studied in connection with thyroid and neuroendocrine function. A full prescribing label was not available in the data reviewed for this summary, so specific label-based claims about mechanism, approved indications, or boxed warnings cannot be confirmed here.
Trial footprint
Protirelin has been studied in 21 registered clinical trials. Example studies include a completed trial examining body weight regulation in patients with narcolepsy, a completed phase 2 study of KPS-0373 in patients with spinocerebellar degeneration, and a completed trial on pharmacogenomic response to thyrotropin-releasing hormone stimulation in healthy volunteers, which looked at a genetic polymorphism affecting serum T3. These trials span neurological and endocrine research areas rather than a single, narrow use.
FAQ
Protirelin is a synthetic peptide that corresponds to thyrotropin-releasing hormone (TRH). It has a molecular weight of about 362.38 g/mol and the chemical formula C16H22N6O4.
This summary is based on available trial and chemical data; a prescribing label was not available for review here, so approved indications cannot be confirmed from this source. Readers should consult official regulatory resources for current approval status.
Protirelin appears in 21 registered clinical trials. Example studies have examined body weight regulation in narcolepsy, spinocerebellar degeneration, and thyroid hormone response in healthy volunteers.
Research sampled here includes a completed study on body weight regulation in patients with narcolepsy and a completed phase 2 trial in spinocerebellar degeneration. Another completed trial looked at how a genetic variation affects thyroid hormone (T3) response after TRH stimulation in healthy volunteers.
No adverse event report data was available in the dataset reviewed for this monograph. Readers should refer to official safety resources or a healthcare provider for side effect information.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-11-07